MRNA Stock Jumps As FDA Backs Flu Shot And Expansion Plans

Moderna Inc. stocks have been trading up by 6.21 percent after promising mRNA trial data boosted investor confidence.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MRNA

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

FDA advisers unanimously backed Moderna’s mRNA-1010/mFLUSIVA flu shot for adults 50–64 and 65+, with an August 5, 2026 PDUFA decision setting a clear regulatory catalyst for MRNA.
After the positive FDA panel vote, MRNA gained about 4% intraday, while Jefferies kept a Hold rating and a $45 target, seeing meaningful flu revenues starting around 2027.
A major restructuring to build three commercial franchises and prep multiple launches in vaccines, oncology, and rare diseases over 2027–2028 pushed Moderna shares up roughly 6.3%.
Reports that the company will invest in German plants, including facilities BioNTech plans to close, sent MRNA up 8–12%, signaling an aggressive European manufacturing expansion.
A June 25, 2026 Investor Science Day will spotlight Moderna’s early pipeline and how its mRNA platform plus AI and robotics is driving faster innovation across new disease areas.

Live Update At 10:03:13 EDT: On Tuesday, June 23, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 6.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has been trading like a momentum rollercoaster. From 2026/05/29 to 2026/06/23, the stock climbed from a close near $47 to about $63, a roughly 34% move in less than a month. The latest daily candle shows Moderna opening around $58.70 and closing near $63.08, with a strong push off the lows into the close. Intraday, MRNA gapped up from the premarket and never looked back, grinding higher from the $59–$60 zone into the low $63s by 10:00.

Under the hood, Moderna is still a high‑burn story. Quarterly revenue sits around $389M, with trailing revenue of about $1.94B. Yet gross margin is only 22.6% and EBIT margin is a steep -140%, reflecting heavy R&D and operating spend. Net income from continuing operations came in at about -$1.34B for the quarter, with EBITDA around -$1.28B and free cash flow about -$692M.

More Breaking News

The balance sheet, however, gives MRNA room to fight. Cash, equivalents, and short‑term investments total roughly $5.2B, versus total liabilities of about $4.08B and modest long‑term debt of $1.25B. Current and quick ratios above 2.0 suggest short‑term liquidity is solid. For traders, that mix — big losses, big cash, and a strengthening chart — creates fertile ground for news‑driven breakouts and sharp pullbacks.

Why Traders Are Watching MRNA Right Now

MRNA is back on the radar because the story has finally shifted away from “post‑COVID hangover” to “next‑gen flu and beyond.” The key catalyst: an FDA advisory committee voted unanimously, 9–0, that Moderna’s mRNA‑1010/mFLUSIVA seasonal flu vaccine has a favorable benefit‑risk profile in adults 50–64 and 65+. That kind of clean, unanimous vote is rare. It strongly supports the Biologics License Application ahead of the August 5, 2026 PDUFA deadline and similar reviews abroad.

Traders responded fast. After FDA advisers backed full approval in adults 50–64 and accelerated approval in those 65+, MRNA popped around 4% intraday. That move showed the market was still pricing in regulatory risk and is now leaning toward eventual approval. But it’s not blind euphoria. Jefferies reiterated a Hold rating and a $45 price target, flagging that meaningful flu revenues likely start in 2027 and grow to roughly $750M in U.S. flu and combo sales by 2030. That’s a medium‑term ramp, not an overnight cash gusher.

At the same time, MRNA is reshaping the entire business. Management announced a restructuring of its operating model and leadership to support three commercial franchises and prepare for multiple launches across vaccines, oncology, and rare diseases in 2027–2028. The stock ripped about 6.3% on that news, making Moderna one of the best S&P 500 performers that day. Traders read it as a clear signal: the company is planning to be more than a one‑hit COVID wonder.

Then came Europe. Reports that Moderna plans to invest in German manufacturing sites — including facilities BioNTech is closing — pushed MRNA up 8–12% across several sessions. That expansion of its European footprint tells traders the company wants serious, independent capacity ahead of a broader product wave. Capacity plus a clean FDA read‑through is a strong combo for sentiment‑driven runs.

Conclusion

For active traders, MRNA now sits at the intersection of regulatory catalysts, corporate restructuring, and aggressive capacity build‑out. The unanimous FDA advisory vote on the mRNA‑1010/mFLUSIVA flu shot gives Moderna a credible path to diversify revenue beyond COVID by 2027, with the August 5, 2026 PDUFA date circled on every catalyst calendar. At the same time, the operating model overhaul and new three‑franchise setup show management is aligning the whole organization around that future pipeline.

MRNA’s price action reflects that changing narrative. A steady march from the mid‑$40s into the low‑$60s, plus strong intraday follow‑through on good news, tells you momentum traders are in control for now. But the core financials still show deep losses and heavy cash burn, even with a solid $5.2B cash cushion. That mix sets the stage for sharp swings as each regulatory headline or pipeline update hits.

The upcoming June 25, 2026 Investor Science Day is the next key waypoint. Moderna plans to showcase how its mRNA platform, combined with AI and robotics, fuels new programs in flu, oncology, and rare disease. Traders will watch closely for fresh data, timelines, and any hint of additional revenue drivers that could justify MRNA’s recent strength.

As Tim Sykes loves to say, “Charts don’t lie, but they also don’t predict — they just show you where traders are excited right now.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.”. With MRNA, the chart, the FDA, and the restructuring story are all signaling the same thing: this is a name to study carefully, trade with a plan, and always manage risk first.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!